Acepodia

Based in the United States, Acepodia is a startup founded in 2018. Its most recent tracked round is Series C+. Brouky classifies it under Software & Developer Tools. Brouky records 1 investor associated with the company.

Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies using its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. The company links tumor-targeting antibodies to proprietary immune cells, such as gamma delta T cells and off-the-shelf natural killer (NK) cells, to create novel antibody cell effector (ACE) therapies.